NCAM1 and myeloid sarcoma: Untreated MS patients’ CD56-bright NK cells show a lower capacity to limit the proliferation of autologous activated T cells, which might be related to CD56 bright NK cell malfunction as well as the discovery that MS CD4 T cells are less susceptible to NK cell regulation [46].